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OBJECTIVES:To evaluate the effectiveness, aswell as the cost-benefit of a hospital-
wide physician educational programme in minimizing the spinal anesthesia (SA)
failure rate.METHODS: A bupivacaine physician educational programme was ini-
tiated in June 2011 tominimize the SA failure rate in the Anesthesia Department of
a tertiary-care hospital in Central Taiwan. We then used the patients recorded in
the institution who underwent SA from January 2010 through December 2011, to
evaluate the effectiveness aswell as the cost-benefit of the programme, taking into
consideration the cost of the training. To minimize potential impact of seasonal
change, we compare two patient cohorts, the pre-training and the post-training
cohorts, that were collected during July to December in 2010 and 2011, respectively.
Logistic regression model was used to evaluate how well the application of the
programme will predict SA failure rate, after controlling for potential impact of
seasonal change. From the payer’s perspective, the cost-benefit of the training was
evaluated by calculating the cost needed under the SA failure rates before and after
the training, based on the true number of patients undergoing SA after the training.
The approved payments from the Bureau of National Health Insurance were used
to do the calculation. RESULTS: There were 1841 and 2372 patients undergoing SA
in the pre-training and post-training periods, respectively. The SA failure rate re-
duced from2.66% to 1.39% in the twoperiods. The training is a predictor of lower SA
failure rate (OR 0.57; 95% CI 0.41-0.79, p0.001). A cost reduction of 3.13% was
noted, indicating the cost-benefit of the training. CONCLUSIONS: The physician
educational programme was associated with a significantly lower SA failure rate,
with a RRR of 43%. Moreover, it had a significant cost-benefit profile from the
payer’s perspective.
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OBJECTIVES: To improve the quality of diabetes care and assist physicians in ac-
quiring the knowledge base and skills required for diabetes management, the dia-
betesmellitus pay-for-performance programwas integratedwith continuingmed-
ical education (CME) and implemented in 2001. Our study examined CME’s
prevalence among physicians and explored the factors associated with variations
in CME participation.METHODS: This cross-sectional comparison study analyzed
the National Health Insurance (NHI) claim data for the year 2008 obtained from the
National Health Research Institutes. Descriptive and multiple logistic regression
analyses were conducted to investigate the factors associated with differential
physician participation in CME. The factors considered included the characteristics
of the physician, the organization, and the regulatory body. RESULTS: A total of
43% of the NHI registry physicians in this study (n  18,284) had diabetes patients
in 2008, but only 7% were participating in DM-P4P. The factors significantly asso-
ciated with participation status were as follows: 1) the physician factor, including
gender, specialty, practice location, number of diabetes patients, and ratio of ma-
jority provider; 2) the organizational factor, including the practice setting and own-
ership; and 3) the regulatory factor, including the time period for implementing the
Diabetes Shared Care Program and the NHI’s regulatory districts. CONCLUSIONS:
This study revealed that under the same financial incentives, physicians had dif-
ferent degrees ofwillingness to participate in the CME,which could be attributed to
the physician, organizational, and regulatory factors. Most of the physicians treat-
ing diabetes in Taiwan were not endocrinologists and their expertise was widely
distributed among diverse specialties. The CME was a key component in develop-
ing physicians’ competencies and driving improvements on national diabetes care
quality; a low level of participationwould however hinder its effects. Policymakers
may need to consider various arrangements for increasing physician participation.
HEALTH CARE USE & POLICY STUDIES - Health Technology Assessment
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NATIONAL HEALTH INSURANCE CLAIMS DATABASE AS A VALUABLE SOURCE
OF INFORMATION FOR HEALTH TECHNOLOGY ASSESSMENT IN TAIWAN
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OBJECTIVES: Health Technology Assessment (HTA) is developed out of the best
scientific evidence in medical, organizational, social, ethical and economic aspect,
to provide decison makers as a decision aid. Health decison makers increasingly
seek information on real-world outcomes; one of such information sources is
administrative claims database. The aim of this study is to explore the types of
information that administrative claims database has been used in the assessment
reports made by Taiwanese HTA agency (CDE/HTA). METHODS: We collected all
the statistics used or analysis results estimated from health insurance database in
the assessment reports that CDE/HTA produced during 2008-2011. These results
were further classified by the indication of the product, type of statistics used, and
sections of the report. Descriptive analysis was performed. RESULTS: There were
34 assessment reports presented statistical data out of National Health Insurance
database in 2008-2011. These included 19 New Drug Applications, 13 Commis-
sioned Research and 2 Medical Device Review. For the types of indications, the
most frequently applied were the drugs used in the area of “the musculoskeletal
systemand connective tissue” and “the nervous systemand sense organs”(18%). Of
all the different types of database used, 65% used longitudinal health insurance
database. Mostly used statistics were “the number of patients using drug” (47%)
and “the number of patients with diagnosis” (38%). “Burden of disease” (47%) and
“budget impact” (32%) were the report sections that presented most of these data.
CONCLUSIONS: At present, most of the CDE/HTA assessments rely on the Longi-
tudinal Health Insurance Database for estimating “the number of patients with
diagnosis” or “the number of patients using drug”. This study has described the
extensively use of claims database in Taiwanese HTA reports. Further usage of
claimsdataset on cost effectiveness analysis or comparative effectiveness research
is expected.
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OBJECTIVES: TheNational Institute for Health and Clinical Excellence (NICE) single
technology appraisal (STA) process was introduced in 2005 as a rapid way to ap-
praise new technologies for use within the NHS in England and Wales. Manufac-
turers are recommended to follow the NICE reference case in presenting clinical
effectiveness and cost-effectiveness evidence in their submissions to NICE. The
purpose of this research was to identify common modeling factors in the manu-
facturer submissions (MS) of expensive technologies that impacted NICE coverage
decisions. METHODS: An analysis of MS and Evidence Review Group reports was
undertaken for 10 technologies (2007-2011) with similar route of administration
and annual treatment cost. Datawas obtained from theNICEwebsite and extracted
on key elements of the strengths and weaknesses of the MS. All STAs were for
drugs with annual treatment costs  £8,000 per year and administered intrave-
nously by injection or infusion. All drug treatments were long-term and indicated
for a range of chronic diseases. RESULTS: Of the 10 STAs, 8 were recommended by
NICE; 4 of the 8 recommended technologies included patient access schemes (PAS).
The duration of the STAs ranged from approximately 36 to 129weeks. Delays in the
STA process were due to poor quality of submissions. Economic evaluations were
either cost-utility or cost-effectiveness analyses. Excel-based Markovmodels were
commonly used to simulate long-term processes.We identifiedmany variations in
the submittedmodels across different characteristics, including calculation of util-
ity values, choice of relevant model population, type of comparator, perspective
and time horizon, inclusion of sensitivity analyses, use of indirect comparison
methods, and availability of systematic literature review. CONCLUSIONS:MS that
were comprehensive, transparent, and internally consistent experience more effi-
cient STA process and positive appraisal outcomes. Manufacturers with expensive
drugs may consider including PAS in their economic evaluations as part of their
submission.
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As Drug Expenditure Rationalization Plan has been implemented in Korea in 2006,
pharmacoeconomics (PE) guidelinewas developed byHealth Insurance Review and
Assessment service (HIRA) to appraise the economic evaluation. Since the imple-
mentation of HIRA PE guideline, various necessities have arisen by the viewers on
how to practically interpret and use the guideline. OBJECTIVES: This survey was
conducted to consolidate opinions of KRPIA (Korean Research-based Pharmaceu-
tical Industry Association) and KPMA (Korea Pharmaceutical Manufacturers Asso-
ciation) on the main issues of the revision of HIRA PE guideline for new medicine.
METHODS: The survey protocol was developed based on the experience of new
drug listing by KRPIA and KPMA members and completed during May 2011 by
e-mails in writing. The key anticipated outcomes were which categories of the
guideline revision the member companies consider necessary RESULTS: Among
KRPIA and KPMA member companies, 19 companies had answered. 63% (n12) of
the subjects answered they could not select the analysis method between CEA and
CUA because HIRA does not appreciate their choices. Among 89% (n17) thosewho
selected to answer the questions regarding detailed guideline for utility study, 71%
(n12) responded they agree with the necessity of the guideline on the condition if
CUA is not applicable CEA could be appreciated. Meanwhile, 26% (n5) responded
they had investigated clinical specialist or patient groups to design and conduct
effectiveness or utility analysis and the most frequently used method was a ques-
tion survey followed by Delphi panel and focus interview. CONCLUSIONS: The
member companies have demands for the revision in the way of operating the
economic evaluation. The key demands are creation of the manual to be followed
for the conduct of economic evaluation study, flexibility of the operation in the
consideration of severity of the indication, efficient and transparent management
of the consultation.
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